Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2012 Earnings Presentation
21 slides from Novo Nordisk A/s Class B's earnings presentation, Apr 27, 2012
Slide 1: Investor conference call: first three months of 2012
Investor Presentation Investor conference call First three months of 2012
Slide 2: Agenda
Investor conference call First three months of 2012 Slide no 2 Agenda Introduction by Lars Rebien Sørensen, CEO Sales update by Lars Rebien Sørensen, CEO R&D update by Mads Krogsgaard Thomsen, CSO Financials and outlook by Jesper Brandgaard, CFO Questions & answers session
Slide 3: Forward-looking statements
Investor conference call First three months of 2012 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2011 and Form 20-F, both expected to be filed wi
Slide 4: Highlights – first three months of 2012
Investor conference call First three months of 2012 Slide no 4 Highlights – first three months of 2012 Sales development • Sales increased by 10% in local currencies driven by modern insulins and Victoza® • Victoza® grew 76% in local currencies and reached DKK 2 billion in sales • Healthcare reforms
Slide 5: Modern insulins and Victoza continue to drive growth
Investor conference call First three months of 2012 Slide no 5 Modern insulins and Victoza® continue to drive growth – first three months of 2012 Sales as reported Growth analysis Other Local currencies Growth Share of Norditropin® (3%) growth +8% 3% Modern insulins 14% 61% 8% Human insulins (1%) (1
Slide 6: Rebound in insulin sales growth rate
Investor conference call First three months of 2012 Slide no 6 Rebound in insulin sales growth rate Novo Nordisk global quarterly insulin sales Key observations MAT growth rate Growth Elements driving rebound in insulin growth rate Quarter vs. same quarter previous year rate… • Annualisation of US h
Slide 7: Encouraging script data on all modern insulin products in the US
Investor conference call First three months of 2012 Slide no 7 Encouraging script data on all modern insulin products in the US US TRx and NBRx script volume market shares NovoLog® NovoLog® Mix Levemir® 80% 80% 80% segment (modern and human insulin) Script volume market share of total 70% TRx NBRx 7
Slide 8: North America continues to drive sales growth
Investor conference call First three months of 2012 Slide no 8 North America continues to drive sales growth – first three months of 2012 Sales as reported Growth analysis Japan & Korea Local currencies Growth Share of 0% growth Region China North America 17% 64% +17% 8% Europe 0% 1% 9% North Americ
Slide 9: Novo Nordisk continues to expand leadership position within diabetes care
Investor conference call First three months of 2012 Slide no 9 Novo Nordisk continues to expand leadership position within diabetes care Global diabetes care market Global diabetes care by treatment class value market share DKK billion Novo Nordisk Lilly BMS GLP-1 Insulin OAD Takeda Merck Novartis T
Slide 10: Victoza continues to exhibit solid underlying growth
Investor conference call First three months of 2012 Slide no 10 Victoza® continues to exhibit solid underlying growth Reported Victoza® sales Victoza® Q1 2012 sales split per region DKK North America Europe China billion Int. Operations Japan & Korea 1% 5% 8% 25% 61% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Sa
Slide 11: Continued expansion of the US GLP-1 market
Investor conference call First three months of 2012 Slide no 11 Continued expansion of the US GLP-1 market Key observations for Victoza® US GLP-1 market expansion in the US market GLP-1 TRx scripts (thousands) GLP-1 % of diabetes market value of TRx retail value (right axis) • 70% of new patients ar
Slide 12: Victoza continues to expand the GLP-1 class in key European markets
Investor conference call First three months of 2012 Slide no 12 Victoza® continues to expand the GLP-1 class in key European markets Development in key European markets following Victoza® launch Germany UK France Market value*: DKK 10 billion Market value*: DKK 5 billion Market value*: DKK 7 billion
Slide 13: Research and Development update
Investor conference call First three months of 2012 Slide no 13 Research and Development update Diabetes care and obesity • Tresiba® and Ryzodeg® have now been submitted in US, EU, Japan, Switzerland, Canada, South Africa, India, Australia, Brazil and Mexico. Tresiba® has also been submitted in Russ
Slide 14: Two clinical trials comparing Tresiba and insulin glargine published in the Lancet
Investor conference call First three months of 2012 Slide no 14 Two clinical trials comparing Tresiba® (insulin degludec) and insulin glargine published in the Lancet The Lancet papers Excerpts from editorial ”Fear of hypoglycaemia or actual hypoglycaemia is commonly the greatest barrier to achievem
Slide 15: New position statement of the ADA and EASD on management of hyperglycaemia in type 2 diabetes
Investor conference call First three months of 2012 Slide no 15 New position statement of the ADA and EASD on management of hyperglycaemia in type 2 diabetes New type 2 diabetes treatment algorithm Key observations Mono- • Focus on consequences of frequent MET therapy hypoglycaemia including: MET +
Slide 16: Public Citizen's petition and Novo Nordisk's response
Investor conference call First three months of 2012 Slide no 16 Public Citizen’s petition and Novo Nordisk’s response Public Citizen’s petition Novo Nordisk observations on Victoza® • Highlighted preclinical and clinical data known by the FDA upon approval of Victoza® • Two completed preclinical stu
Slide 17: Financial results – first three months of 2012
Investor conference call First three months of 2012 Slide no 17 Financial results – first three months of 2012 DKK million Q1 2012 Q1 2011 Change Sales 17,751 15,693 13% Gross profit 14,348 12,576 14% Gross margin 80.8% 80.1% Sales and distribution costs 4,850 4,260 14% Percent of sales 27.3% 27.1%
Slide 18: US dollar and Japanese Yen currently above average
Investor conference call First three months of 2012 Slide no 18 US dollar and Japanese Yen currently above 2011 average 650 Spot rates Quarterly average Annual average Currency 2011 2012 Current assumptions1 average average rate2 600 USD/DKK USD 536 567 565 550 JPY 6.73 7.12 6.96 CNY 83 90 90 500 GB
Slide 19: Financial outlook 2012
Investor conference call First three months of 2012 Slide no 19 Financial outlook 2012 Expectations Previous expectations 27 April 2012 2 February 2012 Sales growth - local currencies 8-11% 7-11% Around 4 percentage points higher than Around 4 percentage points higher than Sales growth - reported gr
Slide 20: Closing remarks
Investor conference call First three months of 2012 Slide no 20 Closing remarks Solid market performance Promising pipeline • +10% annual diabetes care market growth • The only company with two new generation driven by diabetes prevalence1 insulins submitted for approval • 25% market share in diabet
Slide 21: Investor information
Investor conference call First three months of 2012 Slide no 21 Investor information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York